CARE Guiding Principles on Biosimilars

The CARE Faculty has been looking at the impact of biosimilars since 2015, given the significance of this topic across both chronic and disease entities. Select CARE Faculty members have consolidated the following guiding principles based on the collective discussion from past CARE Education initiatives that explored the anticipated impact that the introduction of biosimilars will have in Canada. Biosimilars have been a topic of interest for various CARE™ Faculties for several years now. To gauge levels of understanding along with perceptions and opinions on the impact that biosimilars will have on the Canadian landscape, a number of CARE faculties conducted needs assessments with their peers. Between 2014-2016, needs assessments were directed at specialists in gastroenterology, rheumatology, oncology, and hematology.

Based on these needs assessments, the summit, congress, and post-meeting follow-up, the CARE™ faculty in gastroenterology, rheumatology, oncology/hematology, as well as hospital pharmacy (oncology focus) have subsequently developed guiding principles for their respective specialty. The aim of developing these principles is to provide Canadian health care providers with an overarching view of the positions from the CARE Faculties, which in turn may help inform their treatment decisions. 

What follows is an overview of the guiding principles from the CARE Gastroenterology Faculty, the CARE Rheumatology Faculty, and the CARE Oncology/Hematology Faculty. These guiding principles are subject to update and should be viewed from the lens of today’s data and current views of CARE faculty involved in this output.